#Hereditary Amyloidosis Market Demand

[coherentmicom]

https://www.timessquarereporter.com/health/hereditary-amyloidosis-market-is-estimated-to-witness-high-growth-owing-to-increasing-prevalence-of-amyloidosis

[apurvasstuff]

Global Transthyretin Amyloidosis Treatment Market–Analysis and Demand with Forecast Overview to 2029

Published Date:December 2020

Robust pipeline of transthyretin amyloidosis treatment drugs is one of the major factors that is expected to propel growth of the market over the forecast period.

The global transthyretin amyloidosis treatment market accounted for US$ 40.5 million in 2019 and is anticipated to register a CAGR of 58.7%.

The report "Global Transthyretin Amyloidosis Treatment Market, By Drug (Inostersen, Partisiran, Tafamidis, and Others), By Indication (Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.

Key Highlights:

In August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

In July 2018, Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. received marketing authorization approval for its drug TEGSEDI (inotersen) from the European Commission (EC) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.

Analyst View:

Increasing prevalence of transthyretin amyloidosis

The global transthyretin amyloidosis treatment market is likely to be driven by an increase in the prevalence of disease, rise in the population with African origin, increase in awareness, improvement in diagnostic procedures, improving health care services, rapid economic growth in developing countries, and rise in research and development activity. For instance, According to the Amyloidosis Foundation, there are roughly 126 different genetic variations in ATTR, with up to 53 types of genetic variations in non-transthyretin hereditary amyloidosis diseases. According to reports published on transthyretin amyloidosis, it has been estimated that nearly 10,000, or 1.1 per 100,000 individuals in the world are living with TTR-FAP. The age group of patients suffering from the disorder is between 30 and 40 years of age. It has also been observed that TTR-CM tends to affect older males aged 65 years and above. Familial amyloid polyneuropathy (TTR-FAP) leads to 100 different types of mutations in the transthyretin gene, which leads to protein misfolding. There is only a 50% chance of transferring the mutation to the next generation from an affected parent. On the other hand, the mutation that leads to familial amyloid cardiomyopathy is generally found in individuals of African origin. Amyloidosis related to age primarily affects Caucasian men who are aged 65 years and above.

Increasing healthcare awareness among people

The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, and incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Transthyretin Amyloidosis Treatment Market”, By Drug (Inostersen, Partisiran, Tafamidis, and Others), By Indication (Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029

Key Market Insights from the report:        

The global transthyretin amyloidosis treatment market accounted for US$ 40.5 million in 2019 and is anticipated to register a CAGR of 58.7%. The market report has been segmented on the basis of drug, indication, distribution channel, and region.

Depending upon indication, the hereditary ATTR amyloidosis segment is projected to grow at highest CAGR over the forecast period. The hATTR is caused by the misfolding of protein monomers resulting from the TTR.

Depending upon distribution channel, the hospital pharmacy segment is projected to grow at highest CAGR over the forecast period

By region, North Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.

[latestanalysis]

Europe Genetic Testing Market Top 5 Competitors, Regional Trend, Application, Marketing Strategy, Outlook Analysis and Forecast

Europe Genetic Testing market was valued at US$ 2,472.0 Mn in 2020 and it is projected to reach at US$ 4,262.4 Mn by 2027, at a CAGR of 8.5% during the forecast period. Major factors accounting for this growth include the increase in incidences of genetic, infectious & chronic diseases, reduction in prices of genetic sequencing, rising adoption of precision medicine diagnostic techniques. Genetic testing is defined as medical test which detect changes in proteins, genes or chromosomes. The test results are able to confirm a speculated underlying genetic condition or aid in determining an individual’s chance of developing/ passing on a genetic disorder.

Market Drivers: Increasing focus of government for genetic testing awareness

The growing focus by governments of several countries, to regulate& create awareness regarding genetic tests, has successfully resulted in the faster adoption of these tests worldwide. The rise in Research & Development funding, with the strong market presence by major players in the market, has created a strong entry barrier for new entrants. The increasing innovation in product design, improvement in quality, and strong distribution partnerships are key factors to retain a competitive edge in the market.

Get Sample Copy of this Report @ https://qualiketresearch.com/request-sample/Europe-Genetic-Testing-Market/request-sample

Rising demands for newborn and pre-natal screening to detect congenital abnormalities, growing application of bio banking services that involve DNA testing as a crucial step for cord blood banking are further attributive for progress in this sector. Growing Physicians’ interest towards genetic testing in order to determine patient’s health at various stages of disease development is another factor anticipated to fuel demand in the coming years.

Factors such as increasing implementation of personalized medicine applications to treat chronic disorders enhancing the need for HLA typing & DNA identification for therapy are expected to further add to the growing demand for DNA diagnostics. Moreover, hi-tech advancements which result into commercialization of next generation diagnostic & testing solutions making use of genetic analysis are anticipated to positively impact on Europe genetic testing market growth.

Market Restraints: COVID-19 has negative impact on Europe genetic testing market

The COVID-19 pandemic has left a prominent impact on the growth of the genetic testing market over the crisis. As per the research article published in Genetics in Medicine (2020), all the clinical genetic testing was restricted & telemedicine-based consultations and counseling were adopted across the globe. According to this study, 112 prenatal & 156 clinical genetics/cancer patients were evaluated in a span of one month at the Columbia University Irving Medical Center (CUIMC).

Most of the genetic testing services are adopted virtualization, coupled with home testing kit or home sample collection, to combat the transmission of the SARS-CoV2 virus. Moreover, as per the research article published in the Journal of Medical Genetics (2020), there was hindrance reported in accessing genetic testing blood draws, as a result of that the genetic testing was prominently impacted, wherein a reduction in genetic testing from 97.7% to 74.1% was observed during this period. Hence, COVID-19 is anticipated to have a direct & indirect impact on the genetic testing market over the ongoing crisis period.

Europe Genetic Testing Market Share Analysis by Technology

Based on Technology, the Europe genetic testing market is categorized intoCytogenetics Testing, Biochemical Testing and Molecular Testing.

Cytogenetic testing segment is the second highest revenue generating technology in Europe genetic testing market. The growth is attributed due to rise in healthcare expenditure that has resulted in the increasing use of cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies. Also, cytogenetic is used in the development of targeted cancer treatment, personal medicine, and others. Currently, a wide range of techniques such as comparative genomic hybridization, fluorescence, karyotyping, and others are employed for the screening of genetic abnormalities and cancers. These techniques employ the use of cytogenetic products including media, kits, reagents, and others. This factor is expected to drive the Cytogenetic testing segment over the forecast period.

Europe Genetic Testing Market Share Analysis by Type

Based on type segment, the Europe genetic testing market is categorized into Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive & Presymptomatic Testing, Prenatal Testing and Others.

Diagnostic Testing has accounted for the highest market share in 2020. This is due to rising incidence of genetic and other chronic disorders. As per the information published on World Health Organization (WHO), the increase in prevalence of inherited diseases like sickle cell anemia, cystic fibrosis and hemophilia will contribute the overall market size for genetic tests. Additionally, early disease diagnosis further allows patients to undergo therapeutic treatment at an early stage that minimizes the severity of disease leading to reduced mortality rate and hence proving beneficial for the segment expansion.

Europe Genetic Testing Market Share Analysis by Disease

Based on Disease segment, the Europe genetic testing market is categorized into Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease and Others.

Cancer disease has accounted for the highest market share in 2020. Genetic testing is very helpful to estimate the chances of developing cancer throughout an individual’s lifetime by examining for specific changes in chromosomes and genes, proteins. Cancer, globally, is the 2nd leading reason of death, and approximately70% of deaths from cancer occurs in low- and middle-income countries which raises the demand for genetic testing. As, significant enhancements can be made in the lives of cancer persons by diagnosing at an initial stage & avoiding postponements in care resulting in reduced morbidity, less expensive treatment & greater probability of surviving. This factor creases the demand for genetic testing for cancer.

Europe Genetic Testing Market Share Analysis by Country

Germany, The U.K., Italy and France are top country in Europe genetic testing market. These countries collectively accounted for more than 50% of market share in 2020. The presence of developed healthcare infrastructure, strong government initiatives and proactive funding for genetic testing research, and high prevalence of chronic diseases are the major drivers for industrial growth in these countries.

Other European countries is expected to create significant opportunity in genetic testing due to rising research incentives provided by the government in developing economies of this region that enable R&D and commercialization of technologically advanced products. Moreover, higher availability of target population owing to the incidence of chronic diseases in this region is also expected to supplement growth in the coming years.

Recent Developments:

In March 2020, Abbott had launched molecular point-of-care test to detect novel coronavirus in short time period, 5-15 minutes. The ID NOW platform is small, lightweight & portable (the size of a small toaster), and uses molecular technology, which is valued by clinicians and the scientific community for its high degree of accuracy. ID NOW is already the most widely available molecular point-of-care testing. The company has already shipped 150,000 PCR tests to its existing customers, for use on its m2000 Real-time in vitro diagnostic system.

In March 2021, Qiagen had unveiled its Cloud-based platform, QIAsphere, that helps laboratories & QIAstat-Dx users remotely monitor tests & instrument status around the clock. QIAstat-Dx connectivity with the platform will enable QIAGEN technical service to check customers instrument health in real time, simultaneously offering them a quick response to reduced systems downtime. QIAsphere connectivity is made possible by connecting a small connectivity hub, QIAsphere Base (Qbase), to QIAstat-Dx, as well as other platforms, in less time through LAN or Wi-Fi network of hospitals, retaining sensitive data of patients within the hospital network.

In December 2020, CENTOGENE and Alnylam Pharmaceuticals has launched a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”).

Market Segmentation

The Europe Genetic Testing Market is segmented into type such as Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive & Presymptomatic Testing, Prenatal Testing, and Others. On the basis of Disease, market is segmented into Alzheimer's Disease, Cancer , Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia , Huntington's Disease, and Others. Further, market is segmented into technology such as Cytogenetic Testing, Biochemical Testing, and Molecular Testing.

Also, the Europe Genetic Testing Market is segmented into various countries such as Germany, UK, France, Turkey, Switzerland, Norway, Sweden, Spain, Italy, Denmark, Finland, Iceland, Poland, Luxembourg, Netherlands, and Belgium.

Market Key Players

Various key players are listed in this report such as Abbott Laboratories, Illumina Inc., Eurofins Scientific, Qiagen, Elitech Group, Thermo Fischer Scientific, Centogene AG, Blueprint Genetics, 23andMe Inc., F. Hoffmann-La Roche Ltd, etc.

Market Taxonomy

By Type

Carrier Testing

Diagnostic Testing

Newborn Screening

Predictive & Presymptomatic Testing

Prenatal Testing

Others

By Disease

Alzheimer's Disease

Cancer

Cystic Fibrosis

Sickle Cell Anemia

Duchenne Muscular Dystrophy

Thalassemia

Huntington's Disease

Others

By Technology

Cytogenetic Testing

Biochemical Testing

Molecular Testing

By Country

Germany

UK

France

Turkey

Switzerland

Norway

Sweden

Spain

Italy

Denmark

Finland

Iceland

Poland

Luxembourg

Netherlands

Belgium

Browse Full Research Report @ https://qualiketresearch.com/reports-details/Europe-Genetic-Testing-Market

About Us

QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers. QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition.

[market-insights-dbmr]

Global Amyloidosis Treatment Market 2019 Worldwide Robust Expansion by Top Key Manufactures, Overview, Size, Share, Trends, Segments, Demand and Forecast to 2026

Global amyloidosis treatment market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Emergence of drugs used to treat risk associated with amyloidosis and high demand of disease specific novel therapies are the key factors that fueling the market growth.

Few of the major competitors currently working in the global amyloidosis treatment market are Takeda Pharmaceutical Company Ltd, Arcturus Therapeutics, Inc, Neurimmune, Pfizer Inc, Alnylam Pharmaceuticals, Inc, Proclara Biosciences, Fortress Biotech, Prothena, Spectrum Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc, Johnson & Johnson Services, Inc, Celgene Corporation, Eidos Therapeutics, GlaxoSmithKline plc, Amgen Inc, Fresenius Kabi AG, and others.

Get Sample Copy Of This Report @  https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-amyloidosis-treatment-market

Key Developments in the Market:

In June 2019, Alnylam Pharmaceuticals, Inc received an approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for Onpattro (patisiran), RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR amyloidosis with polyneuropathy. With this approval, represents major advances in the treatment of these patients through targeted mode of action.

In May 2019, Pfizer Inc, received an approval from the FDA for both Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis), an oral transthyretin stabilizers for the treatment of hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. The FDA approval of Vyndaqel and Vyndamax greatly enhance the company’s business portfolio in the therapeutic area of metabolic disorder.

Competitive Analysis:

Global amyloidosis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global amyloidosis treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-amyloidosis-treatment-market

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email: Corporatesales@databridgemarketresearch.com

[marketresearchinsight-blog]

Antisense & RNAi Therapeutics Market Is Growing Rapidly Over The Forecast Period

San Francisco, 15 Nov 2018 - According to a report published by Grand View Research, Inc.; the global antisense and RNAi therapeutics market is projected to be worth around USD 1.81 billion by 2025. Rising use of antisense technology to study gene function for disease management is anticipated to propel market growth over the forecast period (2014 to 2025). This technology regulates expression of disease-causing genes allowing better management of diseases. In addition, increasing R&D for treatment of uncommon neurodegenerative diseases such as hereditary transthyretin amyloidosis (ATTR) is also expected to boost market in near future.

Rising collaborations between pharmaceutical companies and drug delivery service providers are anticipated to drive the market. Antisense therapeutics offer precise and effective gene silencing. Various gene silencing drugs are in late stages of development. Adoption of antisense therapeutics to overcome challenges such as unspecific modes of action and delivery-associated complications are also expected to support market growth in the forthcoming years.

Access Full Insights On Antisense & RNAi Therapeutics Market: www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market

Advancements in personalized therapies based on antisense technology are expected to further propel market expansion. Development of nanotechnology-oriented procedures are expected to create more opportunities in the market. However, issues related to delivering drugs to desired site is the key challenge for market growth. In addition, inevitable toxic effects associated with the antisense and RNAi therapeutics may further hinder the adoption of this technology.

The worldwide antisense and RNAi therapeutics market can be segmented on the basis of technology, application, route of administration, and region. Based on technology, the market can be categorized into RNA interference and antisense RNA. In 2016, RNA interference technology held the largest revenue share due to various advantages of the technology. The RNA interface segment is further bifurcated into Small Interfering RNA (siRNA) and microRNA (miRNA). MiRNA is used to attain deeper understanding related to cancer metastasis as it involves in maintaining identity of cells. SiRNA enables induction at advanced stages of cancer growth as compared to chemotherapy. Thus, adoption of RNAi therapy to target Single Nucleotide Polymorphisms (SNPs) in genetic disorders is likely to propel market during the forecast period.

As per application, the market can be characterized into oncology, cardiovascular, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others. Oncology is anticipated to continue witnessing significant growth over the forecast period due to existence of significant pipeline for cancer therapies. Demand for effective tumor targeting vectorization systems and multiple genes targeting oligonucleotide drugs is expected to grow as nanoparticle systems are affected by inter- and intra-tumor heterogeneity.

On the basis of route of administration, the market for antisense and RNAi therapeutics can be divided into pulmonary delivery, intravenous injections, intradermal injections, topical delivery, intraperitoneal injections, and others. Several studies are being carried out to reduce problems associated with rapid drug elimination without desired pharmacological action. This factor is expected to drive R&D in intravenous injections during the forecast period. Liver is considered as an ideal target for evolving technologies and can be targeted easily by intravenous route. High prevalence of liver disorders like hepatitis B and hepatitis C is likely to drive demand for RNAi therapeutics and antisense nucleotides over the forecast period.

Geographically, the market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America is considered as a key market due to the presence of pipeline RNAi therapeutics in U.S. Several drug applicants under clinical trials have revealed favorable results and are rolling through the development phases. This factor is anticipated to boost regional market over the forecast period.

Prominent companies operating in the antisense and RNAi therapeutics market include Enzon Pharmaceuticals Inc.; Bio-Path Holdings Inc.; Sirnaomics Inc.; Bio-Path Holdings Inc.; and Benitec Biopharma Ltd. Investments in R&D and collaborations remain the key strategies adopted by major market players to attain greater market share. Most companies are also adopting mergers and acquisitions to maintain dominance over other players. This factor is projected to create business opportunities in the forthcoming years.

Access More Reports Of The Same Category: www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global antisense and RNAi therapeutics market on the basis of technology, application, route of administration, and region:

Antisense & RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2014–2025)

RNA Interference

siRNA

miRNA

Antisense RNA

Antisense & RNAi Therapeutics Application Outlook (Revenue, USD Million, 2014–2025)

Oncology

Cardiovascular

Respiratory Disorders

Renal Diseases

Neurodegenerative Disorders

Genetic Disorders

Infectious Diseases

Other

Antisense & RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014–2025)

Pulmonary Delivery

Intravenous Injections

Intradermal Injections

Intraperitoneal Injections

Topical Delivery

Other Delivery Methods

Antisense & RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2014–2025)

North America

US.

Canada

Europe

Germany

UK.

Asia Pacific

Japan

China

Latin America

Brazil

Middle East & Africa

South Africa

Browse Press Release of this Report: www.grandviewresearch.com/press-release/antisense-rnai-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

[monaligvr-blog]

Antisense & RNAi Therapeutics Market Coming To Reach $1.81 Billion By 2025 | Leading Players Marina Biosciences, Benitec Biopharma

San Francisco, 8 October 2018 - According to a report by Grand View Research, Inc., global antisense & RNAi therapeutics market is anticipated to value USD 1.81 billion by 2025. Growing requirement of advanced and effective therapeutics to address rising cases of chronic disorders globally is anticipated to propel demand for antisense & RNAi therapeutics. Antisense technology is likely to offer an opportunity for manipulation of gene expression for treatment of several diseases. It can be used to study gene function for disease management by regulating expression of disease-causing gene.

Continual R&D for treatment of uncommon neurodegenerative diseases such as hereditary ATTR amyloidosis can influence growth of market. Development of antisense therapeutics to overcome challenges related to unspecific modes of action and delivery-associated complications can augment market growth over next few years.

Difficulty in delivering drugs to specific site is expected to become major challenge for use of antisense and RNAi. Drug delivery to nervous tissues can be tough as the drug is supposed to pass blood-brain barrier. In addition, inevitable toxic effects of using these therapeutics can further restrict growth of market over the forecast period. It is necessary to determine right dosage and composition of antisense molecule to reduce Huntington's disease (HD) symptoms and avoid side effects.

Browse Research Report On Antisense & RNAi Therapeutics Market : www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market

The antisense & RNAi therapeutics market can be segregated on the basis of technology, application, route of administration, and region. Based on technology, the market can be categorized into RNA interference and antisense RNA. In 2016, antisense RNA segment dominated the market and accounted for largest market share over the forecast period. Growing use of antisense oligonucleotides to treat neurodegenerative disorders is expected to fuel growth of segment. In addition, implementation of various approaches for prevention of disease onset or halting progressions can influence growth. Diseases such as spinal muscular atrophy and amyotrophic lateral sclerosis are expected to show positive results with use of antisense technology.

Based on application, the market can be classified into oncology, cardiovascular, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and other. Oncology segment is expected to contribute maximum towards growth of market over next few years. Rising cases of eradication disorders such as cancer, HIV, and other mutating viral diseases can augment use of oligonucleotide products. Growing number of clinical trials for oligonucleotide drugs are likely to exhibit growth of segment. In addition, high prevalence of significant pipeline for cancer therapies by companies and institutes can boost segment growth over the forecast period. Moreover, R&D in nanocarriers for oligonucleotide delivery can contribute well to cancer treatment. These nanoparticles can be used to reduce toxicity.

Based on route of administration, the market can be divided into pulmonary delivery, intravenous injections, intradermal injections, intraperitoneal injections, topical delivery, and other delivery methods.

Regional segmentation includes Europe, North America, Asia Pacific, Latin America, and Middle East & Africa (MEA). In North America, the market is expected to witness significant growth over the forecast period. Rising number of RNAi therapeutics currently under developmental pipeline in United States can augment growth of market. Big pharmaceutical developers are likely to enter into collaborations and licensing deals with other smaller firms to boost revenue generation. This, in turn, can fuel market growth over next few years.

Since the discovery of RNAi, there have been efforts to improve treatment methods using RNAi. However, complexities in delivery methodologies associated with RNAi is expected to slow down growth of market. Development of new nanotechnology-oriented methods are likely to re-infuse the market with growth potential during the forecast period.

Moreover, rising number of drug candidates under clinical trials are expected to show favorable results and can progress through development process. This, in turn, can augment market growth over the forecast period.

Some of the leading companies offering antisense & RNAi therapeutics are Olix Pharmaceuticals, GlaxoSmithKline Plc, Alnylam Pharmaceuticals, Benitec Biopharma Ltd., and Antisense Therapeutics Limited. These players are expected to be involved in development of RNAi therapies and platforms that can offer diagnostics, medicines, personalized treatment options for key diseases.

View more reports of this category by Grand View Research at www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global antisense and RNAi therapeutics market on the basis of technology, application, route of administration, and region:

Antisense & RNAi Therapeutics Technology Outlook (Revenue, USD Million, 2014 - 2025)

RNA Interference

siRNA

miRNA

Antisense RNA

Antisense & RNAi Therapeutics Application Outlook (Revenue, USD Million, 2014 - 2025)

Oncology

Cardiovascular

Respiratory Disorders

Renal Diseases

Neurodegenerative Disorders

Genetic Disorders

Infectious Diseases

Other

Antisense & RNAi Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

Pulmonary Delivery

Intravenous Injections

Intradermal Injections

Intraperitoneal Injections

Topical Delivery

Other Delivery Methods

Antisense & RNAi Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Browse Press Release of this Report: www.grandviewresearch.com/press-release/antisense-rnai-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information: www.grandviewresearch.com

[coherentmicom]

https://www.timessquarereporter.com/health/hereditary-amyloidosis-market-is-estimated-to-witness-high-growth-owing-to-increasing-prevalence-of-amyloidosis